CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

125083Orig1s000

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS

LICENSING ACTION RECOMMENDATION

Applicant: Hoffmann-La Roche, Incorporated **STN:** 125083/0

Product:

Peginterferon alfa-2a co-packaged with Ribavirin

Indication / manufacturer's change:

Peginterferon alfa-2a co-packaged with ribavirin

■ Approval:
- Summary Basis For Approval (SBA) included
- ■ Memo of SBA equivalent reviews included

☐ Refusal to File: Memo included
☐ Denial of application / supplement: Memo included

RECOMMENDATION BASIS

■ Review of Documents listed on Licensed Action Recommendation Report

☐ Inspection of establishment ☐ Inspection report included

☐ BiMo inspections completed ☐ BiMo report included

☐ Review of protocols for lot no.(s) _____

☐ Test Results for lot no.(s) _____

Review of Environmental Assessment ☐ FONSI included ■ Categorical Exclusion

■ Review of labeling Date completed 6-3-04 ☐ None needed

CLEARANCE – PRODUCT RELEASE BRANCH

☐ CBER Lot release not required

☐ Lot no.(s) in support – not for release _____

☐ Lot no.(s) for release _____

Director, Product Release Branch _____

CLEARANCE – REVIEW

Review Committee Chairperson _____ Date: 6/4/04

Product Office's Responsible Division Director(s)*: _____ Date: 6/4/04

_____ Date: _____

DMPQ Division Director* _____ Date: 7/11/04

* If Product Office or DMPQ Review is conducted

CLEARANCE – APPLICATION DIVISION

■ Compliance status checked ■ Acceptable ☐ Hold Date: 5/18/04

☐ Cleared from Hold Date: _____

☐ Compliance status check Not Required

Regulatory Project Manager (RPM) Karen D. Weinstock Date: 6-4-04

Responsible Division Director _____ Date: 6/4/04
(where product is submitted, e.g., application division or DMPQ)

7/22/04

Form DCC-201 (04/2003)

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Drug Evaluation and Research

DATE: June 4, 2004

FROM: Karen D. Winestock KDW
Regulatory Project Manager
Division of Review Management and Policy

TO: BL 125083/0

SUBJECT: Administrative Handling Proposal

Dr. Song confirmed receipt of the FDA's June 3, 2004 fax, which contained revised administrative handling proposals. Dr. Song that Roche would comply with the FDA proposals.

In a subsequent call, I stated that Hoffmann-La Roche should note that the FDA's administrative handling proposal did not address all of the required reporting that will be needed (i.e., distribution reports).

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

OFFICE OF NEW DRUGS

OFFICE OF DRUG EVALUATION VI

DIVISION OF REVIEW MANAGEMENT AND POLICY

Woodmont Office Complex II, 6th Floor
1451 Rockville Pike
Rockville, Maryland 20852-1448
FAX #: 301-827-5397

FACSIMILE TRANSMISSION RECORD

TOTAL NUMBER OF PAGES: 4 **(Including Cover Page)**

FAX TO: Dr. Karen Song

Facsimile Telephone No. 973-562-3700 **Voice Telephone No.** 973-562-3812

FROM: Karen Grinestock

Facsimile Telephone No. 301-827-5397 **Voice Telephone No.** 301-827-4358

DATE: 6-3-04 **TIME:** 3:26

MESSAGE: FDA's revised administrative handling proposal.

To: Karen Song, PharmD.
Project Manager
Hoffmann-La Roche, Inc.

From: Karen Winestock, Regulatory Project Manager
FDA, DRMP

Subject: BL 125083/0 - Administrative Handling Proposal

The applicant must comply with all applicable reporting requirements including but not limited to those referenced below. The FDA recommends the following administrative handling proposals for submitting information related to BL 125083/0.

1. Biologic Product Deviation Reports

   - Reports of biological product deviations that are specific to PEGASYS® COPEGUS® Combination Pack (the co-packaged product) should reference BL 125083.

2. Advertising and Promotional Labeling

   - Advertising and Promotional labeling related to the co-packaged product should reference BL 125083.

3. Periodic Adverse Event Reports

   - Adverse events regarding the co-packaged product should reference BL 125083. Identify BL 125083 as the application number in block G.5 of Form FDA 3500A and list PEGASYS® COPEGUS® Combination Pack as the suspect product name. Also cite BL 103964 for peginterferon alfa-2a and NDA 21-511 for ribavirin in block B.5 for reference purposes.

4. Changes to be reported

   - Changes to the Peginterferon alfa-2a or ribavirin, USP should continue to be reported (with all required information) to the respective BLA or NDA, as appropriate (e.g. supplement, annual report)

   - Changes that are specific to the co-packaged product that require a supplement (e.g. new co-packaged product containing 180 ug/1.0 ml vials and Ribavirin) should be reported (with all required information) to BL 125083.

- Annual reports submitted to BL 125083 should contain all information required by 21 CFR601.12 for changes specific to the co-packaged product. In addition, we request that this annual report incorporate by cross-reference all changes that have been reported (via either supplements or annual reports) to BL 103964 or NDA 21-511. We request that this cross-reference information include an itemized list of all the changes, the submission date, the STN# or NDA#, and the status of the change (e.g. pending, approved, implemented) Please include copies of the currently used professional labeling, patient brochures or package inserts (if any), a representative sample of the package labels. (See Attachment A for annual report format proposal)

Attachment A

Annual Report for Pegasys Copegus Combination Pack (STN BL 125083)

A. Changes that are specific to the co-packaging of Pegasys and Copegus are as follows: [NOTE: Include things such as co-packaging of Pegasys vials, new site where the combination pack is packaged, etc.]

1. Changes reported in this Annual Report

2. Changes previously reported to this BLA

Change	Date Reported	Category	Implementation Date	Status

B. List of changes applicable to Pegasys that have been reported to STN BL 103964.

Change	**Labeling revised**	**Previously Reported**			**Implementation Date**	**Status**
		Cross-Reference File	**Date**	**Category**		
		103964/ (b) (4)		CBE		pending
				PAS		

C. List of changes applicable to Copegus that have have reported to NDA 21-511.

Change	**Labeling revised**	**Previously Reported**			**Implementation Date**	**Status**
		Cross-Reference File	**Date**	**Category**		
				CBE		pending
				PAS	Date	approved, implemented

D. Enclosed copies of the currently used professional labeling, patient brochures or package inserts (if any), and a representative sample of the package labels.

FOOD AND DRUG ADMINISTRATION

CENTER FOR DRUG EVALUATION AND RESEARCH

OFFICE OF NEW DRUGS

OFFICE OF DRUG EVALUATION VI

DIVISION OF REVIEW MANAGEMENT AND POLICY

Woodmont Office Complex, 380N
1401 Rockville Pike
Rockville, Maryland 20852-1448
FAX # (301)827-5397

FACSIMILE TRANSMISSION RECORD

TOTAL NUMBER OF PAGES: 5 **(Including Cover Page)**

FAX TO: Dr. Karen Song

Facsimile Telephone No. 973-562-3700 **Voice Telephone No.** 973-562-3812

FROM: Karen Winestock

Facsimile Telephone No. 301-827-5397 **Voice Telephone No.** 301-827-4358

DATE: 5-27-04 **TIME:** _____

MESSAGE: BL 125083/0 FDA's administrative handling proposal.

MAY 2 7 2004

To: Karen Song, Pharm.D.,
Project Manager
Hoffmann-La Roche, Inc.

From: Karen Winestock, Regulatory Project Manager, FDA, DRMP

Subject: BL 125083/0 - Administrative Handling Proposal

The FDA recommends the following administrative handling proposals for submitting data to BL 125083/0.

1. Biologic Product Deviation Reports

   - Biologic deviations that are specific to the co-packaged product should be submitted to BL 125083.

2. Annual reports

   - The individual annual reports should continue to be submitted to the ribavirin NDA and Peginterferon alfa-2a BLA. However, a modified annual report should also be submitted to the co-package BLA. This annual report should contain changes specific to the co-packaged product, a list of labeling changes made during the reporting period, copies of the latest approved labeling and implementation information. The report should also contain a list of manufacturing and labeling changes submitted to BL 103964 and NDA 21-511, the submission date, the STN# or NDA#, the status of the submission. (See Attachment A for annual report format proposal)

3. Advertising and Promotional Labeling

   - Advertising and Promotional labeling related to the co-packaged product should reference the co-package BLA, 125083.

4. Periodic Adverse Event Reports

   - Adverse events specific to the co-packaged product should be submitted to the BL 125083.

5. Supplements

- Changes that are specific to the co-packaged product that require a supplement submission should be submitted to the co-packaged BLA (e.g. new co-packaged product containing 180 ug/1.0 ml vials and Ribavirin).

Attachment A

Annual Report for Pegasys Copegus Combination Pack (STN BL 125083)

A. Changes that are specific to the co-packaging of Pegasys and Copegus are as follows: [NOTE: Include things such as co-packaging of Pegasys vials, new site where the combination pack is packaged, etc.]

1. Changes reported in this Annual Report

2. Changes previously reported to this BLA

Change	Date Reported	Category	Implementation Date	Status

B. All changes applicable to Pegasys have been reported to STN 103964. Changes that were reported, implemented or approved during the reporting period and impact the labeling of the Combination Pack are listed below:

Change	**Previously Reported**			**Implementation Date**	**Status**
	Cross-Reference File	**Date**	**Category**		
				CBE	pending
				PAS	

C. Changes to Copegus have have reported to NDA 21-511. Changes that were reported, implemented or approved during the reporting period and impact the labeling of the Combination Pack are listed below:

Change	**Previously Reported**			**Implementation Date**	**Status**
	Cross-Reference File	**Date**	**Category**		
				CBE	pending
				PAS	

D. (Insert number of copies) XX copies of the currently implemented labeling are enclosed for all labeling that was revised in the reporting period.

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Drug Evaluation and Research

DATE: May 25, 2004

FROM: Karen D. Winestock
Regulatory Project Manager
Division of Review Management and Policy

TO: BL 125083/0

SUBJECT: Carton Labels

I informed Dr. Karen Song that the FDA had reviewed the revised labeling submitted April 19, 2004 and one additional change would be needed. The established names, Peginterferon alfa-2a and Ribavirin, need to be bolded on all of the outer carton labels. Dr. Song notified me that the label for the Copegus tablets currently were be marketed without the established name being bolded. I stated that this label could continue to be marketed in its current format. However, all other labels should follow the format requested above. Dr. Song agreed to make the change and submit the revised labeling to the BLA.

Winestock, Karen

From: Hoyt, Colleen
Sent: Tuesday, May 18, 2004 2:03 PM
To: Winestock, Karen
Subject: RE: Compliance Check Request - STN 125083/0 HL Roche

There have been no inspections at any of the facilities listed below since the issuance of the initial compliance check on 2/24/04, therefore, this updated compliance check is issued to reflect the firm's current compliance status. There are no pending investigations or compliance actions that would prevent approval of STN 125083/0.

Colleen F. Hoyt
Investigations and Preapproval Compliance Branch
OC/DMPQ
(301) 827-8980

-----Original Message-----
From: Winestock, Karen
Sent: Friday, May 07, 2004 1:36 PM
To: Hoyt, Colleen
Subject: Compliance Check Request - STN 125083/0 HL Roche

Good afternoon,

BL 125083/0 is for copackaging Peginterferon alfa-2a with Ribavirin. My previous compliance check has expired. Please do a compliance check on the Peginterferon alfa-2a facilities listed below. The action due date for this BLA is June 6, 2004. However, I would like to approve it no later than May 24, 2004.

Thank you,
Karen
594-5465

-----Original Message-----
From: Hoyt, Colleen
Sent: Monday, February 23, 2004 4:57 PM
To: Syin, Chiang
Cc: Winestock, Karen; Cruz, Concepcion
Subject: Compliance Check - STN 125083/0 HL Roche

There are no pending or ongoing inspections or compliance actions related to the following firms or product. This information is based on a review of district and Center inspections and any pending or ongoing enforcement actions by the Center. It should be noted that the Roche Diagnostics, Penzberg, Germany facility was added to the initial compliance check after submission.

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844
Team Biologics inspection 5/7-16/02 classified VAI
District GMP/NDA inspection 8/12-9/10/03 classified VAI

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200

Team Biologics inspection 9/2-10/02 classified VAI
CDER PAI inspection 11/11-18/02 classified VAI

Roche Diagnostics
Nonnewald 2
Penzburg, Germany
Team Biologics inspection 7/22-29/02 classified VAI

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594

There is no inspectional information entered into FACTS for either biologics or drugs, however, in discussion with Dr. Chiang Syin, CBER, it was established that this facility was inspected on 5/23/03, as part of a CBER preapproval inspection of Hoffman LaRoche, Basel, SZ, for STN 103964/5011, STN 103145/5027, and STN 103749/5038, which was approved on January 7, 2004. CBER personnel do not have entry access to FACTS and a field investigator did not participate in the inspection. This facility is responsible for primary container closure, intermediate packaging, and warehousing of the drug substance.

Colleen F. Hoyt
Investigations and Preapproval Compliance Branch
DMPQ/OC/CDER
U.S. Food and Drug Administration
(301) 827-8980
Email: colleen.hoyt@fda.hhs.gov

-----Original Message-----
From: Syin, Chiang
Sent: Thursday, February 05, 2004 5:38 PM
To: Hoyt, Colleen
Cc: Winestock, Karen
Subject: Compliance Check - STN 125083/0 HL Roche

Please perforem compliance check on (b) (4) STN 125083/0

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594

Thanks.

APPEARS THIS WAY ON ORIGINAL

Winestock, Karen

From: Winestock, Karen
Sent: Friday, May 07, 2004 1:36 PM
To: Hoyt, Colleen
Subject: Compliance Check Request - STN 125083/0 HL Roche

Good afternoon,

BL 125083/0 is for copackaging Peginterferon alfa-2a with Ribavirin. My previous compliance check has expired. Please do a compliance check on the Peginterferon alfa-2a facilities listed below. The action due date for this BLA is June 6, 2004. However, I would like to approve it no later than May 24, 2004.

Thank you,
Karen
594-5465

-----Original Message-----
From: Hoyt, Colleen
Sent: Monday, February 23, 2004 4:57 PM
To: Syin, Chiang
Cc: Winestock, Karen; Cruz, Concepcion
Subject: Compliance Check - STN 125083/0 HL Roche

There are no pending or ongoing inspections or compliance actions related to the following firms or product. This information is based on a review of district and Center inspections and any pending or ongoing enforcement actions by the Center. It should be noted that the Roche Diagnostics, Penzberg, Germany facility was added to the initial compliance check after submission.

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844
Team Biologics inspection 5/7-16/02 classified VAI
District GMP/NDA inspection 8/12-9/10/03 classified VAI

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200
Team Biologics inspection 9/2-10/02 classified VAI
CDER PAI inspection 11/11-18/02 classified VAI

Roche Diagnostics
Nonnewald 2
Penzburg, Germany
Team Biologics inspection 7/22-29/02 classified VAI

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594
There is no inspectional information entered into FACTS for either biologics or drugs, however, in discussion with Dr. Chiang Syin, CBER, it was established that this facility was inspected on 5/23/03, as part of a CBER preapproval inspection of Hoffman LaRoche, Basel, SZ, for STN 103964/5011, STN 103145/5027, and STN 103749/5038, which

was approved on January 7, 2004. CBER personnel do not have entry access to FACTS and a field investigator did not participate in the inspection. This facility is responsible for primary container closure, intermediate packaging, and warehousing of the drug substance.

Colleen F. Hoyt
Investigations and Preapproval Compliance Branch
DMPQ/OC/CDER
U.S. Food and Drug Administration
(301) 827-8980
Email: colleen.hoyt@fda.hhs.gov

-----Original Message-----
From: Syin, Chiang
Sent: Thursday, February 05, 2004 5:38 PM
To: Hoyt, Colleen
Cc: Winestock, Karen
Subject: Compliance Check - STN 125083/0 HL Roche

Please perforem compliance check on (b) (4) STN 125083/0

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594

Thanks.

Chiang Syin, Ph.D.

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research

DATE: February 25, 2004

FROM: Karen D. Winestock KDW
Regulatory Project Manager
Division of Review, Management and Policy

TO: BL 125083/0

SUBJECT: Trade name

Dr. Karen Song called to inform me that the FDA's letter regarding the trade name had been received. She referenced the January 23, 2004 telephone conversation, during which she informed me that Roche found the FDA's proposed trade name acceptable. She asked if she needed to submit revised PI's and Medication Guides incorporating the change.

On February 25, 2004, I left Dr. Song a voice mail message stating that I sent the letter as a formality so that the FDA's comments would become an official part of the file. I noted that she did not need to submit revised labeling incorporating the name change at this time because I was currently working on revising the PI and Medication Guides. I stated that I hoped to receive comments by March 6, 2004.

Winestock, Karen

From: Hoyt, Colleen
Sent: Monday, February 23, 2004 4:57 PM
To: Syin, Chiang
Cc: Winestock, Karen; Cruz, Concepcion
Subject: Compliance Check - STN 125083/0 HL Roche

There are no pending or ongoing inspections or compliance actions related to the following firms or product. This information is based on a review of district and Center inspections and any pending or ongoing enforcement actions by the Center. It should be noted that the Roche Diagnostics, Penzberg, Germany facility was added to the initial compliance check after submission.

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844
Team Biologics inspection 5/7-16/02 classified VAI
District GMP/NDA inspection 8/12-9/10/03 classified VAI

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200
Team Biologics inspection 9/2-10/02 classified VAI
CDER PAI inspection 11/11-18/02 classified VAI

Roche Diagnostics
Nonnewald 2
Penzburg, Germany
Team Biologics inspection 7/22-29/02 classified VAI

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594
There is no inspectional information entered into FACTS for either biologics or drugs, however, in discussion with Dr. Chiang Syin, CBER, it was established that this facility was inspected on 5/23/03, as part of a CBER preapproval inspection of Hoffman LaRoche, Basel, SZ, for STN 103964/5011, STN 103145/5027, and STN 103749/5038, which was approved on January 7, 2004. CBER personnel do not have entry access to FACTS and a field investigator did not participate in the inspection. This facility is responsible for primary container closure, intermediate packaging, and warehousing of the drug substance.

Colleen F. Hoyt
Investigations and Preapproval Compliance Branch
DMPQ/OC/CDER
U.S. Food and Drug Administration
(301) 827-8980
Email: colleen.hoyt@fda.hhs.gov

-----Original Message-----
From: Syin, Chiang

Winestock, Karen

From: Syin, Chiang
nt: Thursday, February 05, 2004 5:38 PM
.o: Hoyt, Colleen
Cc: Winestock, Karen
Subject: Compliance Check - STN 125083/0 HL Roche

Please perforem compliance check or (b) (4) STN 125083/0

Hoffmann-La Roche Inc.
340 Kingsland Street, Bldg. 719/4
Nutley, NJ 07110-1199
FEI: 2210844

F. Hoffmann-La Roche Ltd.
CH-4070
Basel, Switzerland
FEI: 3002807200

F. Hoffmann-La Roche Ltd.
Kaiseraugst Facility
CH-4303
Kaiseraugst, Switzerland
FEI: 3003362594

Thanks.

ıiang Syin, Ph.D.

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research

DATE: December 12, 2003

FROM: Karen D. Winestock
Regulatory Project Manager
Division of Application Review and Policy

TO: BL 125083/0

SUBJECT: Medication Guide Update

I left Dr. Karen Song a voicemail message informing her that the FDA had determined that a single comprehensive Medication Guide for Peginterferon alfa-2a co-packaged with Ribavirin would not be needed. As a result, revised labeling incorporating this change would be needed. In addition, I had performed a cursory review of the COPEGUS package insert and had noticed that the name of the PEGASYS/COPEGUS (b) (4) Pack was listed inconsistently. Prior to submitting revised labeling, Dr. Song should correct this problem. I also stated that I hoped to approve Pegasys in the prefilled syringe by December 24, 2003, which would contain the latest PI and Medication Guide for PEGASYS.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852

Our STN: BL 125083/0

OCT 02 2003

Hoffmann-La Roche, Incorporated
Attention: Karen Song, Pharm.D.
Program Manager, Drug Regulatory Affairs
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Dr. Song:

This letter is in regard to your biologics license application (BLA) submitted under section 351 of the Public Health Service Act.

We have completed an initial review of your application dated August 4, 2003, for Peginterferon alfa-2a copackaged with Ribavirin to determine its acceptability for filing. Under 21 CFR 601.2(a) we have filed your application today. The user fee goal date is June 6, 2004. This acknowledgment of filing does not mean that we have issued a license nor does it represent any evaluation of the adequacy of the data submitted.

At this time, we have not identified any potential review issues. Our filing review is only a preliminary review, and deficiencies may be identified during substantive review of your application. Following a review of the application, we shall advise you in writing of any action we have taken and request additional information if needed.

The regulatory responsibility for review and continuing oversight for this product transferred from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research effective June 30, 2003. For further information about the transfer, please see http://www.fda.gov/cber/transfer/transfer.htm and http://www.fda.gov/OHRMS/DOCKETS/98fr/03-16242.html. Until further notice, however, all correspondence should continue to be addressed to:

CBER Document Control Center
Attn: Office of Therapeutics Research and Review
Suite 200N (HFM-99)
1401 Rockville Pike
Rockville, Maryland 20852-1448

If you have any questions, please contact the Regulatory Project Manager, Karen Winestock, at (301) 827-4358.

Sincerely,

Earl S. Dye, Ph.D.
Acting Director
Division of Review Management and Policy
Office of Drug Evaluation VI
Office of New Drugs
Center for Drug Evaluation and Research

CONCURRENCE PAGE

Letter Type: Filing Notification (FL) & No Deficiencies Identified (NDI)

SS Data Check:
- **Communication**
- **Milestone: Confirm Filing Action Entry & Closed Date**
- **If applicable – Confirm Deficiencies Identified Entry & Closed Date**

cc: Division BLA Files
K. Ayalew, HFM-582
C. Syin, HFM-765
T. Sinha, HFD-530
R. Kambhampati, HFD-530
R. Fleischer, HFD-530

History: K. Winestock,9-25-03: K. Townsend: 9.26.2003: 9.29.2003: 9.30.2003

File Name: (S:\Winestock\BLA\125083\Fling Letter)

Division	Name/Signature	Date
DARP	Karen Winestock	10-1-03
DRMP	Schneider	10-1-03
DRMP	Joyce	10.2-03
DRMP	Kelly Townsend	10-3-03

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research

Date: September 5, 2003

FROM: Karen D. Winestock
Regulatory Project Manager
Division of Application Review and Policy

TO: BL 125083/0

SUBJECT: First Committee Meeting

FDA Attendees: Karen Winestock, Kassa Ayalew, Louis Marzella, Jeffrey Siegel, Russell Fleischer, Tanima Sinha, Rosemary Johann-Liang, Dave Roeder, Carole Broadnax and Chiang Syin

Summary: The review team members acknowledged receipt of their copy of the submission. The DCTDA reviewers found this submission acceptable for filing. Tanima Sinha, the RPM for the Division of Antiviral Drug Products (DAVDP), agreed to poll the reviewers from DAVDP and send Karen Winestock an e-mail on or before 9-21-03 regarding the filing status of the submission. Karen Winestock informed the review team that the only new information that needed to be reviewed consisted of the site and procedure for co-packaging, the ribavirin post marketing commitment and the trade name. As a result, the Office of Therapeutics Research and Review would only expect a review memo from the DMPQ reviewer and possibly the chemist from DAVDP.

Dr. Chiang Syin, the DMPQ reviewer informed the team that the decision regarding the need for an inspection of the site where co-packaging is performed is still under review. A determination would be made after Dr. Syin reviews the data.

The review team was informed that Ms. Leslie Stephens of DSRCS would be the contact person for changes to the Medication Guide. Ms. Stephens had informed Karen Winestock that the Patient Information Subcommittee (PISC) needed to make a recommendation on the proposal for a combined Medication Guide. The PISC would need a one page or one paragraph memorandum that contained background information on the products and the rationale for supplying a combined Medication Guide with the product. The PISC's next meeting would be

held in October 2003. The DCTDA reviewers should discuss this issue with Dr. Marc Walton, prepare the memo and keep DAVDP in the loop. Karen Winestock would need to find out where this memo should be sent.

The team was also informed that Ms. Stephens believed the co-packaging committee needed to be contacted about this submission. However, Mr. David Roeder informed the team that he was a member of the co-packaging committee and that no additional contacts with the committee would be needed.

The team was informed that the action due date for this application is June 6, 2004. However, given the amount of data in this submission, OTRR would like to approve this application by December 2003. Mr. Roeder stated that this date might not be feasible, since the regulatory and procedural issues regarding an application for a co-packaged drug and biologic would need to be discussed with the FDA's legal division. Mr. Mark Kramer of the Office of Combination Products had been informed that this submission had been received and a meeting would be held in the future to discuss these issues.

Dr. Jeffrey Siegel of DCTDA asked for guidance for interacting with DSRCS. The team was informed that the procedures varied from division to division. The decision regarding which division makes the first round of revisions to the labeling is left to the discretion of the primary review division.

The meeting adjourned.

DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20852

AUG 22 2003

Hoffmann-La Roche, Inc.
Attention: Karen Song, Pharm.D.
Program Director
340 Kingsland Street
Nutley, NJ 07110-1199

Dear Dr. Song:

We have received your biologics license application (BLA) submitted under section 351 of the Public Health Service Act for the following biological product:

Our Submission Tracking Number (STN): BL 125083/0

Name of Biological Product: Peginterferon alfa-2a co-packaged with Ribavirin

Indication: Treatment of adults with chronic hepatitis C who have compensated liver disease and who have not been previously treated with interferon alfa

Date of Application: August 4, 2003

Date of Receipt: August 7, 2003

User Fee Goal Date: June 6, 2004

We request that you submit all future correspondence, supporting data, or labeling relating to this application in triplicate, citing the above STN number. The regulatory responsibility for review and continuing oversight for this product transferred from the Center for Biologics Evaluation and Research to the Center for Drug Evaluation and Research effective June 30, 2003. For further information about the transfer, please see http://www.fda.gov/cber/transfer/transfer.htm and http://www.fda.gov/OHRMS/DOCKETS/98fr/03-16242.html. Until further notice, however, all correspondence should continue to be addressed to:

CBER Document Control Center
Attn: Office of Therapeutics Research and Review
Suite 200N (HFM-99)
1401 Rockville Pike
Rockville, Maryland 20852-1448

We will notify you within 60 days of the receipt date if the application is sufficiently complete to permit a substantive review.

If you have any questions, please contact the Regulatory Project Manager, Karen Winestock, at (301) 827-4358.

Sincerely,

Glen D. Jones, Ph.D.
Director
Division of Application Review and Policy
Office of Therapeutics Research and Review
Center for Drug Evaluation and Research

CONCURRENCE PAGE

Letter Type: Acknowledgement Letter (ACK)
Summary Text: STN Assignment - Application

SS & RIS Data Check:
- **If "Unacceptable for Filing" add 2nd LETTER TYPE "UN".**
- **Communication**

RIS Data Check:
- **Submission Screen: In Arrears Box Is Checked**
- **Milestone: Confirm "UN" Entry & User Fees Not Paid -- The Clock Has Stopped. First Action Due Close Date And The New "UN" Entry Date Should Match**
- **No Action Due Date**
- **STN Status – Unacceptable for Filing**

cc: Division BLA Files
Karen Winestock, HFM-588

History: K. Townsend: 8.20.2003

File Name: S:\STN 2003\125083.0.ACK.doc

Office	Name/Signature	Date
DTRR	Karen Winestock	8-21-03
DARP	Deje for Lowe	8-22-03
DARP	Kelly Townsend	8-22-03

MEMORANDUM

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Biologics Evaluation and Research

DATE: Aug 18, 2003

FROM: Marc Walton, M.D.
Acting Deputy Director
Division of Clinical Trial Design and Analysis
Office of Therapeutics Research and Review

SUBJECT: Designation of BLA application review status
Sponsors: Hoffmann-La Roche, Incorporated.
Product: Peginterferon alfa-2a copackaged with Ribavirin
Indications: Treatment of chronic hepatitis C

TO: BL 125083/0

The review status of this file submitted as a BLA application is designated to be:

☒ Standard ☐ Priority

For P.K.

Patricia Keegan, M.D.
Acting Director
Division of Clinical Trial, Design and Analysis
Office of Therapeutics Research and Review
Center for Drug Evaluation and Research

BLA/NDA/PMA
Review Committee Assignment Memorandum

■ Initial Assignment
❑ Change

STN: 125083/0

Applicant: Hoffmann-La Roche, Incorporated

Product: Peginterferon alfa-2a co-packaged with Ribavirin

Addition of committee members

Name	Reviewer Type*	Job Type	Assigned by	Date
Karen Winestock	Reg. Coordinator	Admin/Regulatory	Kay Schneider	8-7-03
	Reviewer	Admin/Regulatory		
Rao Kambhampati	Reviewer	Chemistry	Tanima Sinha	8-15-03
		Product		
		Product		
Kassa Ayalew	Chairperson	Clinical	Louis Marzella	8-18-03
Russell Fleischer	Reviewer	Clinical	Tanima Sinha	8-15-03
		Clinical Pharmacology		
		Pharm/Tox		
		Biostatistics		
		BiMo		
		Epidemiology		
Chiang Syin	Reviewer	Facility/CMC	Chiang Syin	8-8-03
		Inspector		
		Labeling		
		Other		

Deletion of Committee Member

Name	Reviewer Type*	Job Type	Changed by	Date

***reviewer types**: chairperson, consultant reviewer, regulatory coordinator, reviewer, and reg. project mgr (RPM)

Submitted by RPM:

Karen Winestock — Name Printed
Karen Winestock — Signature
8-18-03 — Date

Memo entered in RMS by: DCS Date: 8/21/03 QC by: LB Date: 9-4-03